{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T09:11:52Z","timestamp":1778145112232,"version":"3.51.4"},"reference-count":128,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Heart failure with preserved ejection fraction (HFpEF) is a common clinical syndrome frequently seen in elderly patients, the incidence of which is steadily increasing due to an ageing population and the increasing incidence of diseases, such as diabetes, hypertension, obesity, chronic renal failure, and so on. It is a multifactorial disease with different phenotypic aspects that share left ventricular diastolic dysfunction, and is the cause of about 50% of hospitalizations for heart failure in the Western world. Due to the complexity of the disease, no specific therapies have been identified for a long time. Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2-Is) and Glucagon-Like Peptide Receptor Agonists (GLP-1 RAs) are antidiabetic drugs that have been shown to positively affect heart and kidney diseases. For SGLT2-Is, there are precise data on their potential benefits in heart failure with reduced ejection fraction (HFrEF) as well as in HFpEF; however, insufficient evidence is available for GLP-1 RAs. This review addresses the current knowledge on the cardiac effects and potential benefits of combined therapy with SGLT2-Is and GLP-1RAs in patients with HFpEF.<\/jats:p>","DOI":"10.3390\/ijms232314598","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T09:50:52Z","timestamp":1669197052000},"page":"14598","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3648-9277","authenticated-orcid":false,"given":"Martina","family":"Belli","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy"},{"name":"Cardiovascular Imaging Unit, San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9476-9168","authenticated-orcid":false,"given":"Lucy","family":"Barone","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Bellia","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Sergi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalgisio","family":"Lecis","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1878-8871","authenticated-orcid":false,"given":"Francesca Romana","family":"Prandi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy"},{"name":"Department of Cardiology, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marialucia","family":"Milite","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Galluccio","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4037-7561","authenticated-orcid":false,"given":"Saverio","family":"Muscoli","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Romeo","sequence":"additional","affiliation":[{"name":"Department of Departmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health and Medical Sciences, 00131 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Barill\u00e0","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/eurheartj\/eht117","article-title":"Heart failure with preserved and reduced ejection fraction: Different risk profiles for different diseases","volume":"34","author":"Borlaug","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.hfc.2014.04.011","article-title":"Clinical Trials in Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction","volume":"10","author":"Cleland","year":"2014","journal-title":"Heart Fail. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10741-015-9506-7","article-title":"Heart failure preserved ejection fraction (HFpEF): An integrated and strategic review","volume":"20","author":"Lekavich","year":"2015","journal-title":"Heart Fail. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e004646","DOI":"10.1161\/CIRCHEARTFAILURE.117.004646","article-title":"Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: In- sights from the Get with The Guidelines-Heart Failure Registry","volume":"11","author":"Sharma","year":"2018","journal-title":"Circ. Heart Fail."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jchf.2014.08.004","article-title":"Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients with Heart Failure","volume":"3","author":"Cas","year":"2015","journal-title":"JACC Heart Fail."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e013389","DOI":"10.1161\/JAHA.119.013389","article-title":"SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects","volume":"8","author":"Lam","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/cvr\/cvaa256","article-title":"The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction","volume":"117","author":"Withaar","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel translational insights into the heart failure bene- fits of SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2016.06.061","article-title":"Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure","volume":"68","author":"Johansson","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/eurheartj\/ehs337","article-title":"Predicting survival in heart failure: A risk score based on 39 372 patients from 30 studies","volume":"34","author":"Pocock","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ejhf.679","article-title":"In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: Results from theESC-HFAHeart Failure Long-Term Registry","volume":"19","author":"Targher","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","article-title":"Molecular mechanisms of diabetic cardiomyopathy","volume":"57","author":"Bugger","year":"2014","journal-title":"Diabetologia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 diabetes mellitus and heart failure: A scientific statement from the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","article-title":"Heart Failure in Type 2 Diabetes Mellitus","volume":"124","author":"Kenny","year":"2019","journal-title":"Circ. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jacc.2012.10.028","article-title":"Association between cardiovascular autonomic neuropathy and left ventricular dysfunction: DCCT\/EDIC study (Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications)","volume":"61","author":"Cleary","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1161\/CIRCULATIONAHA.119.041595","article-title":"Coronary Microvascular Dysfunction Is Associated with Myocardial Ischemia and Abnormal Coronary Perfusion during Exercise","volume":"140","author":"Rahman","year":"2019","journal-title":"Circulation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.jacc.2004.09.033","article-title":"Sympathetic dysfunction in type 1 diabetes: Association with impaired myocardial blood \"ow reserve and diastolic dysfunction","volume":"44","author":"Kirkwood","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.120.045888","article-title":"Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The need for further evidence generation and practice guidelines optimization","volume":"142","author":"Khan","year":"2020","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/cvr\/cvaa334","article-title":"Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists","volume":"117","author":"Volpe","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1161\/hc3201.094226","article-title":"Heart Failure with a Normal Ejection Fraction: Is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure?","volume":"104","author":"Zile","year":"2001","journal-title":"Circulation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.revmed.2012.02.004","article-title":"Heart failure with preserved ejection fraction: A systemic disorder?","volume":"33","author":"Ennezat","year":"2012","journal-title":"Rev. Med. Interne"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e002477","DOI":"10.1161\/JAHA.115.002477","article-title":"Clinical Phenotypes in Heart Failure with Preserved Ejection Fraction","volume":"5","author":"Samson","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1056\/NEJMoa051530","article-title":"Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based Study","volume":"355","author":"Bhatia","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0002-9149(00)01393-X","article-title":"Importance of heart failure with preserved systolic function in patients \u226565 years of age","volume":"87","author":"Kitzman","year":"2001","journal-title":"Am. J. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1076-7460.2004.01940.x","article-title":"Diastolic heart failure: A difficult problem in the elderly","volume":"13","author":"Banerjee","year":"2004","journal-title":"Am. J. Geriatr. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJM199212103272408","article-title":"Age and the Cardiovascular System","volume":"327","author":"Epstein","year":"1992","journal-title":"New Engl. J. Med."},{"key":"ref_29","first-page":"109","article-title":"Hemodynamic Aging as the Consequence of Structural Changes Associated with Early Vascular Aging (EVA)","volume":"5","author":"Nilsson","year":"2014","journal-title":"Aging Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1161\/01.CIR.104.2.215","article-title":"Load Versus Humoral Activation in the Genesis of Early Hypertensive Heart Disease","volume":"104","author":"Hart","year":"2001","journal-title":"Circulation"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jchf.2014.05.017","article-title":"Obesity, Subclinical Myocardial Injury, and Incident Heart Failure","volume":"2","author":"Ndumele","year":"2014","journal-title":"JACC Heart Fail."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1161\/01.CIR.0000147184.13872.0F","article-title":"Alterations of Left Ventricular Myocardial Characteristics Associated with Obesity","volume":"110","author":"Wong","year":"2004","journal-title":"Circulation"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1161\/01.HYP.0000090360.78539.CD","article-title":"Measures of Obesity Are Associated with Vascular Stiffness in Young and Older Adults","volume":"42","author":"Wildman","year":"2003","journal-title":"Hypertension"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.amjcard.2006.12.052","article-title":"Comparison of Cardiac Structural and Functional Changes in Obese Otherwise Healthy Adults with Versus without Obstructive Sleep Apnea","volume":"99","author":"Otto","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1378\/chest.121.2.422","article-title":"Severe Obstructive Sleep Apnea Is Associated with Left Ventricular Diastolic Dysfunction","volume":"121","author":"Fung","year":"2002","journal-title":"Chest"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure with Preserved Ejection Fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1152\/physrev.00017.2007","article-title":"Cardiac Remodeling in Obesity","volume":"88","author":"Abel","year":"2008","journal-title":"Physiol. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pcad.2018.07.012","article-title":"Obesity and Cardiac Remodeling in Adults: Mechanisms and Clinical Implications","volume":"61","author":"Alpert","year":"2018","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/ejhf.2064","article-title":"Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial","volume":"22","author":"Anker","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3389\/fphys.2019.01108","article-title":"Chronic Kidney Disease as a Risk Factor for Heart Failure with Preserved Ejection Fraction: A Focus on Microcirculatory Factors and Therapeutic Targets","volume":"10","author":"Broekhuizen","year":"2019","journal-title":"Front. Physiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/eurheartj\/eht066","article-title":"Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND","volume":"34","author":"Brouwers","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ejhf.497","article-title":"Connecting heart failure with preserved ejection fraction and renal dysfunction: The role of endothelial dysfunction and inflammation","volume":"18","author":"Damman","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/eurheartj\/ehy809","article-title":"Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction","volume":"40","author":"Obokata","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_44","first-page":"1146","article-title":"Occlusive disease of the coronary arteries presenting as primary congestive cardiomyopathy","volume":"2","author":"Raftery","year":"1969","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJM200011163432003","article-title":"The Use of Contrast-Enhanced Magnetic Resonance Imaging to Identify Reversible Myocardial Dysfunction","volume":"343","author":"Kim","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/HCO.0b013e32833f0438","article-title":"Evolving focus on diastolic dysfunction in patients with coronary artery disease","volume":"25","author":"Ohara","year":"2010","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0735-1097(86)80453-3","article-title":"Effect of coronary occlusion during percutaneous transluminal angioplasty in humans on left ventricular chamber stiffness and regional diastolic pressure-radius relations","volume":"7","author":"Wijns","year":"1986","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.jacc.2003.11.040","article-title":"Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: Results of the New York heart failure registry","volume":"43","author":"Klapholz","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/aje\/kwt109","article-title":"Contemporary Trends in Heart Failure with Reduced and Preserved Ejection Fraction After Myocardial Infarction: A Community Study","volume":"178","author":"Gerber","year":"2013","journal-title":"Am. J. Epidemiology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.amjmed.2018.12.038","article-title":"Heart Failure with Preserved Ejection Fraction: Is Ischemia Due to Coronary Microvascular Dysfunction a Mechanistic Factor?","volume":"132","author":"Elgendy","year":"2019","journal-title":"Am. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","article-title":"Phenomapping for Novel Classification of Heart Failure with Preserved Ejection Fraction","volume":"131","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_58","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the primary prevention of cardiovascular disease: A report of the american college of cardiology\/American heart association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials","volume":"373","author":"Ray","year":"2009","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14740338.2017.1281246","article-title":"Cardiovascular safety and benefits of GLP-1 receptor agonists","volume":"16","author":"Dalsgaard","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12933-014-0142-7","article-title":"Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists","volume":"13","author":"Saraiva","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The Cardiovascular Biology of Glucagon-like Peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.dsx.2019.01.031","article-title":"Association of fasting glucagon-like peptide-1 with oxidative stress and subclinical atherosclerosis in type 2 diabetes","volume":"13","author":"Alharby","year":"2019","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/jdi.12446","article-title":"Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals","volume":"7","author":"Hirano","year":"2016","journal-title":"J. Diabetes Investig."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s00125-011-2241-2","article-title":"Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice","volume":"54","author":"Nagashima","year":"2011","journal-title":"Diabetologia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"107748","DOI":"10.1016\/j.neuropharm.2019.107748","article-title":"The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke","volume":"158","author":"Yang","year":"2019","journal-title":"Neuropharmacology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.atherosclerosis.2013.08.033","article-title":"Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe\u2212\/\u2212 mice","volume":"231","author":"Burgmaier","year":"2013","journal-title":"Atherosclerosis"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.atherosclerosis.2017.06.920","article-title":"Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits","volume":"265","author":"Sudo","year":"2017","journal-title":"Atherosclerosis"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S1734-1140(13)71069-7","article-title":"Exendin-4 and GLP-1 decreases induced expression of ICAM-1, VCAM-1 and RAGE in human retinal pigment epithelial cells","volume":"65","author":"Dorecka","year":"2013","journal-title":"Pharmacol. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.molimm.2019.09.021","article-title":"Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDL-induced adhesion of monocytes to human endothelial cells: An implication in the treatment of atherosclerosis","volume":"116","author":"Chang","year":"2019","journal-title":"Mol. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00125-017-4330-3","article-title":"The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype","volume":"60","author":"Navarro","year":"2017","journal-title":"Diabetologia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1124\/jpet.119.258343","article-title":"Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators","volume":"370","author":"Bruen","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1160\/TH16-07-0586","article-title":"Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation","volume":"117","author":"Barale","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10557-013-6463-z","article-title":"Glucagon-like Peptide-1 Receptor Agonist Liraglutide Inhibits Endothelin-1 in Endothelial Cell by Repressing Nuclear Factor-Kappa B Activation","volume":"27","author":"Dai","year":"2013","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2017.04.001","article-title":"Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice","volume":"261","author":"Jojima","year":"2017","journal-title":"Atherosclerosis"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12933-016-0480-8","article-title":"Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: An 18-month prospective study","volume":"15","author":"Rizzo","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE\u2212\/\u2212 and LDLr\u2212\/\u2212 Mice by a Mechanism That Includes Inflammatory Pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.atherosclerosis.2019.07.007","article-title":"Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial","volume":"288","author":"Anholm","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/oby.21718","article-title":"Liraglutide causes large and rapid epicardial fat reduction","volume":"25","author":"Iacobellis","year":"2017","journal-title":"Obesity"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2174\/138920011796504509","article-title":"Kidney in Diabetes: From Organ Damage Target to Therapeutic Target","volume":"12","author":"Salvatore","year":"2011","journal-title":"Curr. Drug Metab."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"9927533","DOI":"10.1155\/2021\/9927533","article-title":"The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis","volume":"2021","author":"Tsampasian","year":"2021","journal-title":"Cardiol. Res. Pract."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Muscoli, S., Barill\u00e0, F., Tajmir, R., Meloni, M., Della Morte, D., Bellia, A., Di Daniele, N., Lauro, D., and Andreadi, A. (2022). The new role of SGLT2 Inhibitors in the Management of Heart Failure; current evidence and future perspective. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14081730"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0168-8227(97)01389-2","article-title":"Renal threshold for glucose in non-insulin-dependent diabetic patients","volume":"36","author":"Ruhnau","year":"1997","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2017.07.033","article-title":"Renal glucose metabolism in normal physiological conditions and in diabetes","volume":"133","author":"Alsahli","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2337\/db12-0052","article-title":"Why Do SGLT2 Inhibitors Inhibit Only 30\u201350% of Renal Glucose Reabsorption in Humans?","volume":"61","author":"Liu","year":"2012","journal-title":"Diabetes"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose Transporters in Human Renal Proximal Tubular Cells Isolated from the Urine of Patients with Non\u2013Insulin-Dependent Diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","article-title":"Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes","volume":"72","author":"Zelniker","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ar.1091250303","article-title":"The vascular pattern of the renal glomerulus as revealed by plastic reconstruction from serial sections","volume":"125","author":"Boyer","year":"1956","journal-title":"Anat. Rec."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Prandi, F.R., Barone, L., Lecis, D., Belli, M., Sergi, D., Milite, M., Lerakis, S., Romeo, F., and Barill\u00e0, F. (2022). Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors. Biomolecules, 12.","DOI":"10.3390\/biom12101349"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.kint.2017.10.020","article-title":"Reduced cortical oxygenation predicts a progressive decline of renal function in patients with chronic kidney disease","volume":"93","author":"Pruijm","year":"2018","journal-title":"Kidney Int."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1111\/dom.13823","article-title":"Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes","volume":"21","author":"Mulder","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"F767","DOI":"10.1152\/ajprenal.00565.2018","article-title":"Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy","volume":"317","author":"Lee","year":"2019","journal-title":"Am. J. Physiol Renal. Physiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"19323","DOI":"10.1038\/s41598-022-24103-x","article-title":"Empagliflozin protects against renal ischemia\/reperfusion injury in mice","volume":"12","author":"Wang","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12967-022-03629-8","article-title":"SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease","volume":"20","author":"Lu","year":"2022","journal-title":"J. Transl. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"844","DOI":"10.14740\/jocmr2760w","article-title":"Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys","volume":"8","author":"Sano","year":"2016","journal-title":"J. Clin. Med. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"ref_97","first-page":"S36","article-title":"Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits","volume":"124","author":"Verma","year":"2019","journal-title":"Am. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s13300-020-00885-z","article-title":"Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies","volume":"11","author":"Alshnbari","year":"2020","journal-title":"Diabetes Ther."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Chiba, Y., Yamada, T., Tsukita, S., Takahashi, K., Munakata, Y., Shirai, Y., Kodama, S., Asai, Y., Sugisawa, T., and Uno, K. (2016). Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0150756"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/HJH.0000000000001434","article-title":"Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2","volume":"35","author":"Matthews","year":"2017","journal-title":"J. Hypertens."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrates utilization in response to sodium-glucose co-transporter-2 inhibition in nondiabetic subjects and type 2 diabetic patients","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV Protection in the EMPA-REG OUTCOME trial: A \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: Rationale and design of the DELIVER trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_108","first-page":"17","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"13","author":"Steiner","year":"2016","journal-title":"Z. Gefassmed."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1093\/eurheartj\/ehaa419","article-title":"A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: The DAPA-LVH trial","volume":"41","author":"Brown","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium\u2013Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.12578","article-title":"Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition","volume":"18","author":"Rajeev","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.2337\/dc16-1312","article-title":"Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals with Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?","volume":"39","author":"Verma","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: A pilot study","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12933-017-0497-7","article-title":"The renal tubular damage marker urinary N-acetyl-\u03b2-d-glucosaminidase may be more closely associated with early detection of atherosclerosis than the glomerular damage marker albuminuria in patients with type 2 diabetes","volume":"16","author":"Kim","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12933-016-0473-7","article-title":"Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome","volume":"15","author":"Kusaka","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_122","first-page":"1","article-title":"Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: Randomized placebo-controlled trial","volume":"18","author":"Bizino","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jacc.2010.10.042","article-title":"Effect of Obesity and Overweight on Left Ventricular Diastolic Function: A community-based study in an elderly cohort","volume":"57","author":"Russo","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/CIRCRESAHA.114.301958","article-title":"Cardiovascular Actions of Incretin-Based Therapies","volume":"114","author":"Ussher","year":"2014","journal-title":"Circ. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/dom.14363","article-title":"Effects of 6weeks of treatment with dapagliflozin, a sodiumglucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study","volume":"23","author":"Oldgren","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_127","first-page":"4020492","article-title":"GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes","volume":"2018","year":"2018","journal-title":"J. Diabetes Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s10741-021-10106-9","article-title":"New antidiabetic therapy and HFpEF: Light at the end of tunnel?","volume":"27","author":"Tadic","year":"2021","journal-title":"Heart Fail. Rev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/23\/14598\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:25:03Z","timestamp":1760145903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/23\/14598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":128,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["ijms232314598"],"URL":"https:\/\/doi.org\/10.3390\/ijms232314598","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,23]]}}}